Jacob Robinson, an entrepreneurial scientist and CEO of Motif Neurotech, discusses the future of mental health treatment through innovative neuromodulation implants aimed at depression. Joined by Brom Rector of Empath Ventures, they unveil how these minimally invasive devices could revolutionize psychiatry, offering alternatives to traditional drug therapies. The conversation touches on ethical considerations, challenges of accessibility, and the differentiation between Motif and Neuralink. They also explore the transition from academic research to innovative entrepreneurship in the neurotechnology space.